rs6814664 — SLC2A9 SLC2A9 Uric Acid Transport Variant

SLC2A9 rs6814664 — An Intronic Tag Variant for Urate Transport Regulation

Your kidneys filter about 700 mg of uric acid daily, reabsorbing most of it back into the bloodstream. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, also called GLUT9, a voltage-driven urate transporter expressed in the proximal tubule of the kidney that handles most renal urate reabsorption — the protein responsible for setting your urate "baseline." The rs6814664 C>T variant sits within an intron of SLC2A9 and does not change the protein itself, but tags a broader regulatory signal that modulates how much urate your kidneys return to the bloodstream.

This variant is part of a cluster of intronic SLC2A9 SNPs identified in genome-wide association studies as tagging the same biological signal: variation in GLUT9 transport efficiency. As a tag SNP, rs6814664 captures the urate association through linkage disequilibrium with functional variants elsewhere in the gene.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a (long form) located on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the blood, and GLUT9b (short form) on the apical membrane. Together they form a "urate-recapture" system: urate filtered from blood enters the tubular lumen, is reabsorbed by apical transporters including URAT1, and then re-enters the circulation via GLUT9a.

Intronic variants in SLC2A9 are thought to exert their effects through altered gene expression rather than protein structure changes. The SLC2A9 locus contains active enhancers in hepatic and erythroid cell types, and fine-mapping studies²² fine-mapping studies
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 identify epistatic interactions between intronic and intergenic variants that together explain about 6% of serum urate variance. The rs6814664 C allele likely tags regulatory haplotypes that drive higher GLUT9 expression or greater transport efficiency, resulting in more urate being returned to the blood.

The Evidence

Sex-specific effects are the defining feature of SLC2A9 intronic variants. The landmark KORA genome-wide scan by Döring et al.³³ Döring et al.
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 (n = 1,644 primary cohort plus three replication samples) showed that intronic SLC2A9 variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men but a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele copy, with women showing up to twice the effect size of men in replication cohorts. Separately, SLC2A9 isoform 2 expression was significantly associated with serum urate, explaining 3.5% of variance in men and 15% in women. This sex divergence likely reflects estrogen-mediated regulation of GLUT9 expression and the lower baseline urate levels in women, where relative changes are more detectable.

The SLC2A9 locus overall was characterised by Vitart et al.⁴⁴ Vitart et al.
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 as the single strongest genetic determinant of serum urate, with variants explaining 1.7–5.3% of urate variance across Croatian, UK, and German samples. Variants at this locus were also associated with reduced fractional excretion of uric acid (less urate in the urine), confirming that the mechanism is impaired renal excretion rather than overproduction.

BMI interaction: A study in the Bruneck and Utah cohorts⁵⁵ study in the Bruneck and Utah cohorts
Döring A et al. Sex-specific association of SLC2A9 variants with uric acid levels is modified by BMI. 2008 (n = 2,669) found that SLC2A9 intronic variant effects on serum urate are amplified in individuals with higher BMI, with significant interaction p-values of 0.023–0.035. This means that C-allele carriers who are also overweight or obese accumulate a greater urate burden than the genetic effect alone would predict.

Population variation: The C allele shows striking population stratification: ~90% in East Asians, ~57% in Europeans, ~32% in Africans. This gradient mirrors the known cross-ancestry differences in serum urate and gout prevalence — East Asian populations, who carry the highest C-allele burden at this locus, also have among the highest gout prevalence globally.

Practical Actions

Intronic SLC2A9 variants affect urate reabsorption efficiency. Dietary and metabolic levers that directly modulate the urate load reaching those transporters are the most tractable interventions.

The key dietary modulators of serum urate for C-allele carriers are: organ meats (liver, kidney, sweetbreads) and red meat, which supply large purine loads; alcohol — particularly beer and spirits, which elevate urate both through purine content and by competing with urate for renal excretion; and high-fructose beverages, since fructose catabolism generates inosine monophosphate (a direct urate precursor) and fructose itself competes with urate for tubular exchange via SLC2A9. Dairy and coffee are associated with modestly lower serum urate in epidemiological studies.

The crystalisation threshold for monosodium urate is 6.8 mg/dL at physiological temperature. Maintaining serum urate below 6.0 mg/dL is a widely used clinical target to prevent and dissolve crystals and suppress gout flares.

Interactions

With rs3733591 (SLC2A9 Arg265His): rs3733591 is the larger-effect coding variant at SLC2A9, with the C allele adding ~0.65 mg/dL per copy in some studies. rs6814664 tags an independent intronic signal. Individuals carrying C alleles at both loci accumulate risk from two mechanistically distinct SLC2A9 sources — both should be examined to estimate total SLC2A9-attributed urate load.

With rs11942223 (SLC2A9 intronic, independent signal): rs11942223 is a second independent intronic SLC2A9 signal (LD with rs6814664 is partial but not complete). Carriers of risk alleles at both intronic loci have additive urate elevation and should consider more aggressive dietary restriction of fructose and purines.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. C-allele carriers at rs6814664 who also carry the ABCG2 Q141K T allele face urate accumulation from two independent routes — impaired renal clearance and impaired gut excretion — substantially increasing gout risk.

With BMI: The interaction between SLC2A9 genotype and BMI is one of the better-replicated gene-environment interactions for serum urate. CC homozygotes who are overweight or obese face compounded risk beyond what either factor predicts alone; weight management has outsized benefit in this group.